Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Peng

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Genome Biology|November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticityWon-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Genome Biology|November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticityWon-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Pageof 6